Tradestie Institutional Equity Comparison Engine

DNA vs EVMN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

EVMN Overall Edge

EVMN Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Evommune, Inc. (EVMN) driven by superior Growth & Margin, Options & Structure while DNA counters with relative strength in Momentum & Technical. Fundamentally, DNA trades at N/M Forward P/E with -202.5% operating margin (-5.7% YoY revenue) versus EVMN at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, DNA sits in BREAKDOWN (34th %ile IV; Dealer Gamma Walls on Pro) against EVMN sits in SURGE (53rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
DNA N/M vs EVMN N/M Fwd P/E
Growth & Margin Winner EVMN
Op Margin -202.5% vs 0.0% ยท YoY -5.7% vs +0.0%
Momentum & Technical Winner DNA
1Y +6.2% vs -61.0% ยท 52W Pos 24% vs 8%
Options & Structure Winner EVMN
BREAKDOWN (34th %ile IV) vs SURGE (53rd %ile IV)
DNA NYSE
Ginkgo Bioworks Holdings, Inc.
Biological Products, (No Disgnostic Substances)
$8.50
-11.55% 1D
Market Cap $623.0M
1M Return -17.23%
1Y Return +6.25%
Forward P/E N/M
Unified AI Score
56.0 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 68.0 Mom 50.0
EVMN US Equity
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap $315.5M
1M Return +37.33%
1Y Return -61.03%
Forward P/E N/M
Unified AI Score
30.0 / 100 SELL
Tech 50.0 Fund 35.0 Flow 69.0 Mom 44.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DNA +6.25% EVMN -61.03% Spread: +67.28 pp (DNA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period DNA Revenue EVMN Revenue DNA Op. Margin EVMN Op. Margin Margin Edge
FY2019 $50M N/A -132.1% N/A DNA
FY2020 $80M N/A -178.8% N/A DNA
FY2021 $310M N/A -582.6% N/A DNA
FY2022 $480M N/A -462.4% N/A DNA
FY2023 $250M N/A -343.8% N/A DNA
FY2024 $230M $10M -246.5% -1000.2% DNA
FY2025 $170M $10M -185.3% -623.6% DNA

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DNA (4) vs EVMN (4)
Institutional Metric DNA EVMN Criterion Row Winner
Market Capitalization Scale $623.0M $315.5M Larger Scale DNA
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -5.7% +0.0% Higher Growth EVMN
Operating Margin (TTM) Profitability -202.5% 0.0% Higher Margin EVMN
Net Profit Margin Profitability -192.0% 0.0% Higher Margin EVMN
Return on Equity (ROE) Capital Efficiency -58.2% -69.5% Higher ROE DNA
52-Week Range Position Momentum 24% ($5โ€“$18) 8% ($5โ€“$33) Stronger Trend DNA
Beta / 30D Volatility Risk Regime 3.14ฮฒ ยท 152% Vol 1.05ฮฒ ยท 118% Vol Lower Realized Risk EVMN
Unified Institutional Score Composite Signal 56.0 / 100 (HOLD) 30.0 / 100 (SELL) Higher Composite DNA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DNA vs EVMN Buy Guide
DNA BREAKDOWN
30d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 34th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live DNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
EVMN SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 53rd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live EVMN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DNA nor EVMN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.